Insulin initiation and intensification in patients with T2DM for the primary care physician

被引:15
|
作者
Unger, Jeff [1 ]
机构
[1] Catalina Res Inst, 14726 Ramona Ave,Suite 110, Chino, CA 91710 USA
关键词
diabetes; basal; bolus; regimens; insulin analogs; structured glucose testing;
D O I
10.2147/DMSO.S14653
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes mellitus (T2DM) is characterized by both insulin resistance and inadequate insulin secretion. All patients with the disease require treatment to achieve and maintain the target glycosylated hemoglobin (A1C) level of 6.5%- 7%. Pharmacological - management of T2DM typically begins with the introduction of oral medications, and the majority of patients require exogenous insulin therapy at some point in time. Primary care physicians play an essential role in the management of T2DM since they often initiate insulin therapy and intensify regimens over time as needed. Although insulin therapy is prescribed on an individualized basis, treatment usually begins with basal insulin added to a background therapy of oral agents. Prandial insulin injections may be added if glycemic targets are not achieved. Treatments may be intensified over time using patient-friendly titration algorithms. The goal of insulin intensification within the primary care setting is to minimize patients' exposure to chronic hyperglycemia and weight gain, and reduce patients' risk of hypoglycemia, while achieving individualized fasting, postprandial, and A1C targets. Simplified treatment protocols and insulin delivery devices allow physicians to become efficient prescribers of insulin intensification within the primary care arena.
引用
收藏
页码:253 / 261
页数:9
相关论文
共 50 条
  • [41] T2DM patients with depression have higher levels of hyperglycemia and cognitive decline than T2DM patients
    Thummasorn, Savitree
    Apichai, Sopida
    Chupradit, Supat
    Sirisattayawong, Pornpen
    Chaiwong, Pachpilai
    Sriwichaiin, Sirawit
    Pratchayasakul, Wasana
    Chattipakorn, Nipon
    Chattipakorn, Siriporn C.
    PLOS ONE, 2022, 17 (08):
  • [42] Association Analysis of Insulin Resistance and Osteoporosis Risk in Chinese Patients with T2DM
    Wang, Xinshui
    Jiang, Lijuan
    Shao, Xiaonan
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2021, 17 : 909 - 916
  • [43] Basal insulin persistence in Brazilian participants with T2DM
    Franco, Denise Reis
    Perez-Nieves, Magaly
    Ivanova, Jasmina I.
    Cao, Dachuang
    Caselato Vaz, Marcela Saturnino
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2019, 65 (10): : 1254 - 1264
  • [44] Serial Online Education Helps Break Down Primary Care Practitioner Barriers to Insulin Therapy for T2DM Management
    Turell, Wendy
    Drexel, Carole
    Beaser, Richard S.
    DIABETES, 2020, 69
  • [45] Age and Other Factors Predicting Insulin Intensification Strategies in Patients With Type 2 Diabetes (T2DM) Uncontrolled on Oral Diabetes Medication (ODM)
    Korytkowski, Mary T.
    Lombardero, Manuel
    Brooks, Maria M.
    Orchard, Trevor J.
    Kanter, Justin
    Dealmeida, Dilhari
    Siminerio, Linda M.
    DIABETES, 2013, 62 : A650 - A650
  • [46] Postabsorptive and insulin-stimulated leucine metabolism in offspring of T2DM patients
    Sereni, LP
    Ruggieri, D
    Benedini, S
    Battezzati, A
    Luzi, L
    Perseghin, G
    DIABETES, 2004, 53 : A334 - A334
  • [47] Improved Insulin Secretion Following Intrapancreatic UCB Transplantation in Patients With T2DM
    Tong, Qiang
    Duan, Lian
    Xu, Zihui
    Wang, Hui
    Wang, Xiaocui
    Li, Zhongjun
    Zhang, Weizhen
    Zheng, Hongting
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (09): : E1501 - E1504
  • [48] Physician beliefs in efficacy of insulin glargine (GLAR) are associated with glucose control in type 2 diabetes (T2DM)
    Herman, W.
    Zhang, Q.
    Kennedy, L.
    DIABETOLOGIA, 2006, 49 : 527 - 528
  • [49] Lixisenatide Added to Basal Insulin Reduces Glycemic Variability in T2DM Patients
    Umpierrez, Guillermo E.
    Digenio, Andres
    Goldenberg, Ronald
    Hernandez-Triana, Eric
    Lin, Jay
    O'Neal, David
    Park, Cheol-Young
    Renard, Eric
    Kovatchev, Boris
    DIABETES, 2014, 63 : A260 - A260
  • [50] Pioglitazone (PIO) enhances insulin sensitivity (IS) in patients with type 2 diabetes (T2DM)
    Johns, D
    Herz, M
    Tan, MH
    Robertson, KE
    Gonzalez, B
    Reviriego, J
    Grossman, LD
    DIABETES, 2002, 51 : A102 - A102